4CPS-019 Abstract withdrawn

<h3>Background and Importance</h3> The Selection Visit (SV) of a clinical trial (CT) determines whether the site meets the Sponsor’s requirements. The decision to include a site in a specific clinical trial depends on numerous factors, with the characteristics and service portfolio of the Pharmacy Service (PS) being particularly significant. <h3>Aim and Objectives</h3> To analyse the results and evolution of selection visits for clinical trials conducted in the Pharmacy Service at a tertiary hospital during the period from 2014 to 2023. <h3>Material and Methods</h3> Retrospective, observational study. All selection visits conducted in the PS during the period from 2014 to 2023 were included. Data were extracted from PS’s SV registry and the CT management programme. Collected data included the date of the SV, protocol code, sponsor, clinical service of the principal investigator, studied pathology, acceptance/rejection of the centre, and whether the reason for rejection was related to the PS. <h3>Results</h3> During the study period, 247 SVs were conducted, broken down by year of SV: 16 (6%) in 2014; 23 (9%) in 2015; 33 (13%) in 2016; 22 (9%) in 2017; 24 (10%) in 2018; 18 (7%) in 2019; 26 (11%) in 2020; 20 (8%) in 2021; 26 (11%) in 2022; 39 (16%) in 2023. Average SV/year: 25 (range 16–39). In 95% of the SVs conducted, the trial sponsor was the pharmaceutical industry, compared to 5% (12 SVs) where the sponsor was an independent research group. The clinical service with the highest number of SVs was Rheumatology with 82 SVs (33%), followed by Endocrinology 40 (16%); Cardiology 27 (11%); Internal Medicine 25 (10%); Urology 18 (7%); Neurology 16 (7%); and other services 39 (16%). The centre was selected in 148/247 (60%) visits. In none of the cases was the reason for the centre’s rejection related to the PS. <h3>Conclusion and Relevance</h3> This study shows an upward trend in the number of selection visits conducted and the number of times the centre is chosen. In no case was the reason for rejection due to the Pharmacy Service. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest

Authors

Institutions

Publication Details

Published
2025-03-01
DOI
https://doi.org/10.1136/ejhpharm-2025-eahp.94
Primary Topic
Statistical Methods in Clinical Trials
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

4CPS-019 Abstract withdrawn

MI Martín-Herranz, Patricia Sanchez‐Carballo, MT Rabuñal-Alvarez, E. Mira et al.
Statistical Methods in Clinical Trials
article

4CPS-019 Abstract withdrawn

MI Martín-Herranz, Patricia Sanchez‐Carballo, MT Rabuñal-Alvarez, E. Mira, M Calvín-Lamas, S Jimeno-Aguado
article en

Abstract

<h3>Background and Importance</h3> The Selection Visit (SV) of a clinical trial (CT) determines whether the site meets the Sponsor’s requirements. The decision to include a site in a specific clinical trial depends on numerous factors, with the characteristics and service portfolio of the Pharmacy Service (PS) being particularly significant. <h3>Aim and Objectives</h3> To analyse the results and evolution of selection visits for clinical trials conducted in the Pharmacy Service at a tertiary hospital during the period from 2014 to 2023. <h3>Material and Methods</h3> Retrospective, observational study. All selection visits conducted in the PS during the period from 2014 to 2023 were included. Data were extracted from PS’s SV registry and the CT management programme. Collected data included the date of the SV, protocol code, sponsor, clinical service of the principal investigator, studied pathology, acceptance/rejection of the centre, and whether the reason for rejection was related to the PS. <h3>Results</h3> During the study period, 247 SVs were conducted, broken down by year of SV: 16 (6%) in 2014; 23 (9%) in 2015; 33 (13%) in 2016; 22 (9%) in 2017; 24 (10%) in 2018; 18 (7%) in 2019; 26 (11%) in 2020; 20 (8%) in 2021; 26 (11%) in 2022; 39 (16%) in 2023. Average SV/year: 25 (range 16–39). In 95% of the SVs conducted, the trial sponsor was the pharmaceutical industry, compared to 5% (12 SVs) where the sponsor was an independent research group. The clinical service with the highest number of SVs was Rheumatology with 82 SVs (33%), followed by Endocrinology 40 (16%); Cardiology 27 (11%); Internal Medicine 25 (10%); Urology 18 (7%); Neurology 16 (7%); and other services 39 (16%). The centre was selected in 148/247 (60%) visits. In none of the cases was the reason for the centre’s rejection related to the PS. <h3>Conclusion and Relevance</h3> This study shows an upward trend in the number of selection visits conducted and the number of times the centre is chosen. In no case was the reason for rejection due to the Pharmacy Service. <h3>References and/or Acknowledgements</h3> <h3>Conflict of Interest</h3> No conflict of interest

Complexo Hospitalario Universitario A Coruña (ES)
Openalex Percentile: Top 95%
Statistical Methods in Clinical Trials
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.